Published in Aust Prescr on December 05, 2016
Treating patients on new anticoagulant drugs. Aust Prescr (2016) 0.91
Treating patients on new anticoagulant drugs. Aust Prescr (2017) 0.75
Pharmacokinetics of apixaban. Aust Prescr (2017) 0.75
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96
Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med (2015) 8.38
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol (2013) 4.58
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation (2014) 3.53
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ (2015) 2.83
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64
Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Med J Aust (2012) 1.36
Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis (2011) 1.30
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis. Intern Med J (2014) 1.25
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J (2014) 1.12
Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler Thromb Vasc Biol (2015) 1.02
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost (2013) 0.95
Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. Semin Thromb Hemost (2015) 0.94
Is the ideal anticoagulant a myth? Expert Rev Clin Pharmacol (2012) 0.92
Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nat Rev Cardiol (2014) 0.89
Idarucizumab. Aust Prescr (2016) 0.87
How to manage warfarin therapy. Aust Prescr (2015) 0.86
Which patients may benefit from dose adjustment of non-vitamin K antagonist oral anticoagulants? Semin Thromb Hemost (2015) 0.80
Patients' perspectives regarding long-term warfarin therapy and the potential transition to new oral anticoagulant therapy. Ther Adv Drug Saf (2014) 0.80
Selecting an oral anticoagulant for patients with nonvalvular atrial fibrillation. J Thromb Thrombolysis (2015) 0.78